Signifor (Pasireotide Diaspartate) Patent Expiration, LOE Window & CMS Spending
Signifor (Pasireotide Diaspartate) by Recordati Rare Diseases: FDA Orange Book core substance LOE 2026-12-14, 0 AB generics, $2.4M 2024 CMS Part D & Medicaid spend, and 27 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Recordati Rare Diseases |
| FDA Application & Pathway | N200677 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | 2026-12-14 |
| Last Listed Patent or Exclusivity Date | 2026-12-14 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $2.4M |
| 2024 Medicare Part D Spend | $2.1M |
| 2024 Medicaid Spend | $335K |
| Reported Wholesale Price Change (CA SB 17) | 27 WAC filings (max 37.8% 2-yr change) |